Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy
|ClinicalTrials.gov Identifier: NCT01056601|
Recruitment Status : Terminated (Funding not available)
First Posted : January 26, 2010
Results First Posted : August 26, 2011
Last Update Posted : December 28, 2017
|Condition or disease||Intervention/treatment||Phase|
|Pancreatic Cancer||Drug: Bortezomib Drug: Panobinostat||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||7 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase II Study of Panobinostat (LBH589) Given in Combination With Bortezomib (Velcade) in Patients With Pancreatic Cancer Progressing on Gemcitabine Therapy Alone or Gemcitabine in Combination|
|Study Start Date :||September 2010|
|Primary Completion Date :||February 2011|
|Study Completion Date :||February 2011|
Experimental: Pancreatic Cancer Patients
Pancreatic cancer patients who received treatment with bortezomib and panobinostat after progressing on gemcitabine.
1.3 mg/m^2 administered intravenously twice daily on days 1 and 8 for 2 weeks followed by 10 day rest period
Other Name: VelcadeDrug: Panobinostat
20 milligrams administered orally 3 times weekly for 2 weeks on Days 1,3,5,8,10 and 12 followed by 9 day rest period
Other Name: LBH589
- Progression-Free Survival [ Time Frame: Up to 1 Year ]Median number of months before disease progressed in patient on gemcitabine when treated with the combination of panobinostat and bortezomib. Progression free survival is measured from randomization until the subject has documented disease progression by an objective measure. Subjects must be alive with no more than 20% increase in tumor size to qualify for progression free survival. Changes in tumor size are defined by RECIST criteria.
- Number of Participants by Tumor Response [ Time Frame: Up to 1 Year ]Number of patients whose tumor has responded to study therapy is determined using Response Evaluation Criteria In Solid Tumors. Progressive Disease (PD) is assessed if the sum of the diameters has increased by ≥ 20% and ≥ 5 mm from nadir (including baseline if it is the smallest sum). Objective response is measured by tumor reduction as defined in the RECIST criteria. Tumor shrinkage must be at least 30% to qualify as an objective response.
- Duration of Response [ Time Frame: Up to 1 Year ]Duration of response is calculated as (Date of First Disease Progression or Death as a Result of any Cause whichever Comes First - Date of First Objective Status Assessment of Confirmed Complete or Partial Response as defined by RECIST criteria).
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01056601
|United States, Minnesota|
|Masonic Cancer Center, University of Minnesota|
|Minneapolis, Minnesota, United States, 55455|
|Principal Investigator:||Arkadiusz Dudek, MD||Masonic Cancer Center, University of Minnesota|